What it's for (Indications)
- Treatment of hyperthyroidism, including Graves' disease, toxic multinodular goitre, and toxic adenoma.
- Carbimazole is also extensively used in the preparation of hyperthyroid patients for definitive treatments such as thyroidectomy or radioactive iodine therapy, aiming to achieve a euthyroid state to reduce surgical risks or enhance the effectiveness of radioiodine.
- Furthermore, it can be employed for the long-term management of hyperthyroidism in individuals for whom surgery or radioactive iodine treatment are contraindicated, unsuitable, or undesirable.
- It can also be used as part of a regimen to manage thyrotoxic crisis, often in conjunction with other supportive therapies.
- This therapeutic agent is crucial for controlling excessive thyroid hormone production and mitigating the systemic effects of thyrotoxicosis across various clinical scenarios.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of carbimazole must be individualized based on the patient's thyroid function, severity of hyperthyroidism, and clinical response. Initial doses typically range from 20 mg to 60 mg daily, often administered in two or three divided doses to maintain consistent therapeutic levels, although single daily dosing may be considered for compliance. Once the patient achieves a euthyroid state, which usually takes 4-8 weeks, the dose is gradually reduced to a maintenance level, commonly between 5 mg and 15 mg daily. An alternative strategy, known as the "block and replace" regimen, involves administering a higher, fixed dose of carbimazole (e.g., 40 mg/day) to completely suppress thyroid hormone synthesis, followed by concomitant administration of levothyroxine to maintain euthyroidism. This regimen is often used for long-term treatment to prevent drug-induced hypothyroidism and simplify dosing. For pediatric patients, dosages are typically adjusted according to body weight and clinical response, with careful monitoring. Regular monitoring of thyroid hormones (T3, T4, TSH) is essential to guide dose adjustments throughout the treatment course. |
Safety & Warnings
Common Side Effects
- Carbimazole treatment can lead to a variety of side effects, ranging from mild and transient to severe and life-threatening.
- Common adverse reactions include nausea, vomiting, headache, pruritus (itching), urticaria (hives), skin rash, arthralgia (joint pain), and mild, reversible hair loss.
- These tend to be more frequent at the initiation of therapy and often resolve spontaneously or with symptomatic treatment.
- More serious, albeit less common, side effects necessitate immediate medical attention and potential discontinuation of the drug.
- These include severe haematological disturbances such as agranulocytosis (a critical reduction in granulocytes, increasing infection risk), aplastic anaemia, and thrombocytopenia.
- Hepatic dysfunction, manifesting as elevated liver enzymes, cholestatic jaundice, or even fulminant hepatic failure, is another significant concern.
- Reports of acute pancreatitis, vasculitis (including ANCA-positive vasculitis), nephritis, and a lupus-like syndrome have also been documented.
- Over-treatment can lead to iatrogenic hypothyroidism, requiring dose adjustment or the addition of thyroid hormone replacement.
- Patients should be counselled on recognizing and promptly reporting any concerning symptoms.
Serious Warnings
- Black Box Warning: While carbimazole does not carry a formal FDA Black Box Warning (as it is not FDA-approved in the US, and its active metabolite methimazole does not have one), several severe and potentially life-threatening adverse reactions warrant prominent and urgent safety warnings, akin to the gravity of a boxed warning. **1. Severe Agranulocytosis:** Carbimazole can induce severe, rapidly onsetting, and potentially fatal agranulocytosis, characterized by a profound reduction in granulocytes, which are crucial for fighting infection. Patients must be explicitly instructed to immediately report any signs of infection, such as fever, sore throat, oral ulcers, or unexplained bruising/bleeding. A complete blood count (CBC) with differential must be performed immediately upon suspicion, and treatment with carbimazole must be discontinued if agranulocytosis is confirmed. This adverse effect typically occurs within the first few months of therapy but can manifest at any time. **2. Severe Hepatotoxicity:** Carbimazole therapy has been associated with severe, idiosyncratic hepatotoxicity, including cholestatic jaundice, hepatocellular damage, and, in rare instances, fulminant hepatic failure requiring liver transplantation or resulting in death. Patients must be advised to promptly report any symptoms indicative of liver dysfunction, such as jaundice (yellowing of skin or eyes), dark urine, pale stools, persistent nausea, vomiting, or abdominal pain. Liver function tests should be monitored at baseline and periodically during treatment, and carbimazole should be immediately discontinued if significant liver injury is detected. A history of liver damage from carbimazole or thiamazole is a contraindication. **3. Acute Pancreatitis:** Cases of acute pancreatitis, some of which have been severe and required hospitalization, have been reported in patients receiving carbimazole or its active metabolite, thiamazole. Patients presenting with sudden, severe abdominal pain often radiating to the back, possibly accompanied by nausea and vomiting, should seek immediate medical attention. Treatment must be discontinued if acute pancreatitis is diagnosed. Patients with a history of acute pancreatitis after carbimazole or thiamazole administration should not be re-challenged with the drug. **4. Congenital Malformations:** Carbimazole's active metabolite, thiamazole (methimazole), crosses the placenta and has been associated with congenital malformations, including aplasia cutis congenita (absence of skin in patches), choanal atresia/esophageal atresia, omphalocele, omphalomesenteric duct abnormalities, and ventricular septal defects, especially when administered during the first trimester of pregnancy. While untreated hyperthyroidism also poses significant risks to pregnancy, women of childbearing potential should be thoroughly counselled about these risks. If antithyroid drug therapy is required during pregnancy, propylthiouracil (PTU) is generally preferred during the first trimester due to its lower placental transfer risk in early pregnancy, with a potential switch to carbimazole/methimazole in the second or third trimester.
- Several critical warnings are associated with carbimazole therapy due to the potential for serious adverse effects.
- Patients must be thoroughly counselled on the warning signs of agranulocytosis, such as sore throat, fever, mouth ulcers, or any signs of infection, and instructed to seek immediate medical attention if these symptoms develop.
- Baseline and regular monitoring of complete blood counts (CBC) with differential, particularly during the initial months of treatment, is crucial to detect this potentially fatal complication early.
- Similarly, patients should be educated about symptoms indicative of liver dysfunction, including jaundice, dark urine, pale stools, persistent nausea, vomiting, or unexplained fatigue, and advised to report them promptly.
- Liver function tests (LFTs) should be monitored at baseline and periodically.
- The occurrence of acute pancreatitis, characterized by severe abdominal pain, nausea, and vomiting, also warrants immediate investigation and drug discontinuation.
- Furthermore, the teratogenic potential of carbimazole and its active metabolite, methimazole, especially during the first trimester of pregnancy, is a significant concern, with reported associations with congenital malformations.
- Women of childbearing potential require thorough counselling, and alternative therapies like propylthiouracil (PTU) may be preferred during early pregnancy.
- Carbimazole also passes into breast milk, requiring careful consideration during lactation.
How it Works (Mechanism of Action)
Carbimazole itself is a prodrug that possesses minimal pharmacological activity. Following oral administration, it is rapidly and almost completely metabolized in vivo into its active metabolite, thiamazole, also known as methimazole. Thiamazole primarily exerts its antithyroid effects by inhibiting the enzyme thyroid peroxidase (TPO) within the thyroid gland. This enzyme plays a pivotal role in the biosynthesis of thyroid hormones, triiodothyronine (T3) and thyroxine (T4), through two main mechanisms. Firstly, TPO catalyzes the oxidation of iodide ions (I-) to active iodine, which is then necessary for the iodination of tyrosine residues on the thyroglobulin protein. Secondly, TPO facilitates the coupling reactions of monoiodotyrosines (MIT) and diiodotyrosines (DIT) to form T3 and T4. By blocking these critical steps, thiamazole effectively reduces the synthesis and release of new thyroid hormones from the follicular cells, leading to a gradual decrease in circulating T3 and T4 levels and thereby alleviating the symptoms of hyperthyroidism. It is important to note that carbimazole does not inhibit the release of pre-formed thyroid hormones stored in the colloid, nor does it inactivate circulating hormones, which accounts for the lag period before clinical improvement is observed.
Commercial Brands (Alternatives)
No other brands found for this formula.